




Daniela Y Santiesteban, PhD¹, Aundrietta D Duncan, PhD¹, Justine Delgado, PhD¹, Vincent Jacques, PhD^{1,2}, Sheila DeWitt, PhD^{1,2} and Swami P Iyer, MD³ ¹Salarius Pharmaceuticals, Inc., Houston, TX; ²DeuteRx, LLC, Andover, MA; ³Department of Lymphoma/Myeloma, The University of Texas at MD Anderson Center, Houston, TX

INTRODUCTION

SP-3164, an oral, next-generation molecular glue, is currently in INDenabling studies and is expected to enter the clinic in 2023. SP-3164 interacts with the cereblon (CRBN) component of a CRL4 E3 ligase, inducing recruitment and subsequent degradation of hematological transcription factors, Ikaros (IKZF1) and Aiolos (IKZF3). SP-3164 incorporates deuterium to stabilize the (S)-enantiomer of avadomide (CC-122), an extensively studied clinical drug candidate, preventing interconversion to the undesired (R)-enantiomer. SP-3164 has shown compelling activity in preclinical models of Non-Hodgkin lymphomas (NHL) and may have advantages over other molecular glues.







Deuterated (*R*)-avadomide

- No protein degradation No anticancer activity
- Potentially supports
- tumor growth

OBJECTIVE

To characterize SP-3164's protein degradation and anticancer activity and demonstrate its therapeutic potential in NHLs, including follicular lymphoma (FL).

METHOD(S)

- Quantitative proteomics: Jeko-1 cells were treated for 4 hrs with SP-3164 (0.5 μM or 5 μ M) or lenalidomide (10 μ M). Protein abundance was determined by LC-MS-based protein quantification.
- **Protein degradation:** PBMCs were treated with SP-3164 for 6 hrs and Aiolos degradation was assessed by western blot.
- In vitro viability: PBMCs were plated and treated with SP-3164 (9 concentrations) for 96 hrs and viability assessed with CellTiterGlo®
- **Apoptosis/degradation**: JeKo-1 cells were treated with SP-3164 for 48 hours and stained for cleaved caspase-3 and lkaros and analyzed by flow cytometry. Data shown is relative to DMSO control.
- Cytokine secretion: Human T cells, isolated from healthy donor PBMCs (n=6), were treated with a 10-point dose-response curve of SP-3164 or SP-3165 (d-R-CC-122) for 6 hrs. Soluble cytokine targets were measured in media using the Meso Scale Discovery assay system.
- In vivo efficacy: Female CB17/SCID mice (n=10) were inoculated with 5X10⁶ DOHH-2 (FL) cells and treated with test agent(s) when tumors reached ~110 mm³. Tumor samples were collected at 2 hrs after the last dosing and stained for Ikaros and Aiolos.


EHA2023


A Novel Cereblon-Binding Molecular Glue, SP-3164, Shows Preclinical **Activity In Non-Hodgkin Lymphomas**



RESULTS

Quantitative Proteomics Reveals Potency of SP-3164-Induced Degradation





d-R-CC-122 (SP-3165) does not induce cytokine secretion at clinically relevant concentrations.

CONCLUSIONS


• SP-3164, the deuterium-stabilized (S)-enantiomer of avadomide, is a novel molecular glue with compelling antitumor activity in NHL models. • SP-3164 is more potent than lenalidomide, inducing 2-fold more degradation of neosubstrates 1/10 the dose. • Quantitative proteomics reveal a PDE6 as neo-substrate unique to SP-3164 when compared to lenalidomide. • In vitro immunomodulation studies validate SP-3164 as the active species and that the (R)-enantiomer has minimal effects. • SP-3164 potently and efficiently degrades lkaros and Aiolos in PBMCS in a time- and dose dependent manner. • In cancer cells, SP-3164 degrades Ikaros and Aiolos, induces apoptosis, and reduces viability in vitro. • In in vivo FL studies, SP-3164 showed compelling single agent TGI and when combined with venetoclax or tazemetostat resulted in more pronounced TGI. • The preclinical data support the clinical evaluation of SP-3164 in lymphomas. A Phase 1 clinical trial is planned to start in H2 2023.

CONTACT INFORMATION



SP-3164 Induces Degradation In Vivo

Apoptosis Correlates with Ikaros Degradation



JeKo-1 apoptosis, as measured by cleaved caspase 3 expression, correlated with extent of Ikaros degradation at 48 hrs.

SP-3164 Demonstrates Potent In Vivo Anti-tumor single agent and commination activity

B. FL Xenograft Model Combo with Tazemetostat Tumor Volume ±SEM - vehicle - SP-3164 (7.5 mg/kg BID) <u>ک</u> 3000- tazemetostat (300 mg/kg BID) SP-3164 (7.5 mg/kg BID) + 2000tazemetostat (300 mg/kg BID) 1000[.] Days on Study

SP-3164's activity was studied in a mouse model of follicular lymphoma (FL, DOHH2) as a single agent and in combination. A) With venetoclax, SP-3164 showed improved tumor growth inhibition (TGI) compared to either agent alone. B) With tazemetostat (TAZ), SP-3164 performed better than the approved agent, which had no effect. In combination, SP-3164

dsantiesteban@salariuspharma.com

JUNE 8 - 15 / FRANKFURT & VIRTUAL